难治性-话题@MedSci

#难治性#

683篇内容 | 2697人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1528782, encodeId=99371528e826f, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：伊沙佐米+皮下注射利妥昔单抗+地塞米松可有效治疗复发或难治性巨球蛋白血症！, objectType=article, longId=215762, objectId=968f215e627f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=968f215e627f, replyNumber=0, likeNumber=52, createdTime=2021-08-17, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=968f215e627f, moduleTitle=J Clin Oncol：伊沙佐米+皮下注射利妥昔单抗+地塞米松可有效治疗复发或难治性巨球蛋白血症！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=968f215e627f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528781, encodeId=15ff1528e81e3, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！, objectType=article, longId=215591, objectId=5479215591c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5479215591c2, replyNumber=0, likeNumber=28, createdTime=2021-08-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5479215591c2, moduleTitle=Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5479215591c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528780, encodeId=b84c1528e80f4, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：长春新碱+伊立替康联合或不联合替莫唑胺治疗儿童和成人复发或难治性横纹肌肉瘤的疗效：随机II期研究, objectType=article, longId=215317, objectId=7c8e21531ec8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c8e21531ec8, replyNumber=0, likeNumber=61, createdTime=2021-08-06, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c8e21531ec8, moduleTitle=J Clin Oncol：长春新碱+伊立替康联合或不联合替莫唑胺治疗儿童和成人复发或难治性横纹肌肉瘤的疗效：随机II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c8e21531ec8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528779, encodeId=f0461528e7945, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：3期| 乐伐替尼在中国放射性碘难治性分化型甲状腺癌患者中的疗效, objectType=article, longId=215211, objectId=48cb2152117d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48cb2152117d, replyNumber=0, likeNumber=80, createdTime=2021-08-04, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48cb2152117d, moduleTitle=Clin Cancer Res：3期| 乐伐替尼在中国放射性碘难治性分化型甲状腺癌患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48cb2152117d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528778, encodeId=cab41528e78d0, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Eur J Cancer：紫杉醇在氟嘧啶和铂类难治性食管鳞癌中的效果明显优于多西他赛！, objectType=article, longId=215144, objectId=fb9b21514490, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb9b21514490, replyNumber=0, likeNumber=104, createdTime=2021-08-03, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb9b21514490, moduleTitle=Eur J Cancer：紫杉醇在氟嘧啶和铂类难治性食管鳞癌中的效果明显优于多西他赛！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb9b21514490)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528777, encodeId=dc211528e77b8, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Hematol Oncol：塞利尼索(selinexor)治疗复发/难治性弥漫大B淋巴细胞瘤的疗效：SADAL研究, objectType=article, longId=215018, objectId=3aeb21501886, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aeb21501886, replyNumber=0, likeNumber=52, createdTime=2021-07-31, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aeb21501886, moduleTitle=J Hematol Oncol：塞利尼索(selinexor)治疗复发/难治性弥漫大B淋巴细胞瘤的疗效：SADAL研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3aeb21501886)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528776, encodeId=fce81528e76ac, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤, objectType=article, longId=214948, objectId=920821494873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=920821494873, replyNumber=0, likeNumber=57, createdTime=2021-07-29, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=920821494873, moduleTitle=Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=920821494873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528775, encodeId=5e381528e75b5, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , objectType=article, longId=214902, objectId=ef3021490202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef3021490202, replyNumber=0, likeNumber=57, createdTime=2021-07-29, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef3021490202, moduleTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef3021490202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528774, encodeId=e9021528e74ed, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet：肾动脉超声消融治疗难治性高血压效果明显（RADIANCE-HTN TRIO研究）, objectType=article, longId=214816, objectId=bc212148160f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc212148160f, replyNumber=0, likeNumber=105, createdTime=2021-07-27, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc212148160f, moduleTitle=Lancet：肾动脉超声消融治疗难治性高血压效果明显（RADIANCE-HTN TRIO研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc212148160f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528773, encodeId=68c51528e73b5, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=EuroIntervention：肾动脉超声消融治疗难治性高血压长期随访结果公布（RADIANCE-HTN SOLO研究）, objectType=article, longId=214815, objectId=a05f2148157b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a05f2148157b, replyNumber=0, likeNumber=65, createdTime=2021-07-27, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a05f2148157b, moduleTitle=EuroIntervention：肾动脉超声消融治疗难治性高血压长期随访结果公布（RADIANCE-HTN SOLO研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a05f2148157b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528772, encodeId=208d1528e720d, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效, objectType=article, longId=214279, objectId=44752142e9a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44752142e9a0, replyNumber=0, likeNumber=74, createdTime=2021-07-17, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44752142e9a0, moduleTitle=Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44752142e9a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528771, encodeId=74471528e7132, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Allergy Clin Immunol Pract：利多卡因喷雾剂可有效减少难治性慢性咳嗽患者的咳嗽频率, objectType=article, longId=214255, objectId=47f0214255a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47f0214255a5, replyNumber=0, likeNumber=75, createdTime=2021-07-16, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47f0214255a5, moduleTitle=J Allergy Clin Immunol Pract：利多卡因喷雾剂可有效减少难治性慢性咳嗽患者的咳嗽频率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47f0214255a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528770, encodeId=63c01528e706f, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Nat Med：局部输注HER2特异性CAR-T细胞治疗复发性/难治性中枢神经系统肿瘤儿童和年轻患者的临床研究, objectType=article, longId=214242, objectId=a2d6214242c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2d6214242c7, replyNumber=0, likeNumber=91, createdTime=2021-07-16, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2d6214242c7, moduleTitle=Nat Med：局部输注HER2特异性CAR-T细胞治疗复发性/难治性中枢神经系统肿瘤儿童和年轻患者的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2d6214242c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528769, encodeId=9f3e1528e6946, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Int J Hematol：罗米布司汀可有效治疗艾曲波帕难治性再生障碍性贫血, objectType=article, longId=214202, objectId=1c69214202fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c69214202fe, replyNumber=0, likeNumber=63, createdTime=2021-07-15, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c69214202fe, moduleTitle=Int J Hematol：罗米布司汀可有效治疗艾曲波帕难治性再生障碍性贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c69214202fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528768, encodeId=20a01528e682b, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Molecular Cell:难治性乳腺癌的潜在药物靶点：RNA结合蛋白YTHDF2, objectType=article, longId=213710, objectId=20da213e10b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20da213e10b4, replyNumber=0, likeNumber=106, createdTime=2021-07-05, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20da213e10b4, moduleTitle=Molecular Cell:难治性乳腺癌的潜在药物靶点：RNA结合蛋白YTHDF2, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20da213e10b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528767, encodeId=40381528e67e0, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol: 帕博利珠单抗+GVD（吉西他滨、长春瑞宾和脂质体阿霉素）二线治疗复发或难治性经典霍奇金淋巴瘤的疗效和安全性, objectType=article, longId=213317, objectId=1fc021331e00, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fc021331e00, replyNumber=0, likeNumber=58, createdTime=2021-06-28, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fc021331e00, moduleTitle=J Clin Oncol: 帕博利珠单抗+GVD（吉西他滨、长春瑞宾和脂质体阿霉素）二线治疗复发或难治性经典霍奇金淋巴瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fc021331e00)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528766, encodeId=6d6c1528e6621, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Eur J Cancer：瑞戈非尼或可成为复发性/难治性实体肿瘤患儿的新选择！, objectType=article, longId=213192, objectId=82032131929f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82032131929f, replyNumber=0, likeNumber=95, createdTime=2021-06-26, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82032131929f, moduleTitle=Eur J Cancer：瑞戈非尼或可成为复发性/难治性实体肿瘤患儿的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82032131929f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528765, encodeId=706f1528e65f4, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解, objectType=article, longId=213190, objectId=1a3a21319035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a3a21319035, replyNumber=0, likeNumber=97, createdTime=2021-06-26, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a3a21319035, moduleTitle=J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a3a21319035)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528764, encodeId=d8911528e64c6, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Leukemia：研究支持首次复发后的复发/难治性多发性骨髓瘤患者使用D-RD, objectType=article, longId=213161, objectId=686921316115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686921316115, replyNumber=0, likeNumber=70, createdTime=2021-06-25, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686921316115, moduleTitle=Leukemia：研究支持首次复发后的复发/难治性多发性骨髓瘤患者使用D-RD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686921316115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528763, encodeId=8f841528e63c6, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, objectType=article, longId=212816, objectId=bee72128164e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee72128164e, replyNumber=0, likeNumber=61, createdTime=2021-06-18, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee72128164e, moduleTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bee72128164e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

难治性

2020-05-29

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：伊沙佐米+皮下注射利妥昔单抗+地塞米松可有效治疗复发或难治性巨球蛋白血症！

2021-08-17

仁者大医 (审核中...)

前往app查看评论内容

#难治性#

Lancet：双特异性抗体Teclistamab有望成为复发性/难治性多发性骨髓瘤的新疗法！

2021-08-13

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：长春新碱+伊立替康联合或不联合替莫唑胺治疗儿童和成人复发或难治性横纹肌肉瘤的疗效：随机II期研究

2021-08-06

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：3期| 乐伐替尼在中国放射性碘难治性分化型甲状腺癌患者中的疗效

2021-08-04

freve (审核中...)

前往app查看评论内容

#难治性#

Eur J Cancer：紫杉醇在氟嘧啶和铂类难治性食管鳞癌中的效果明显优于多西他赛！

2021-08-03

freve (审核中...)

前往app查看评论内容

#难治性#

J Hematol Oncol：塞利尼索(selinexor)治疗复发/难治性弥漫大B淋巴细胞瘤的疗效：SADAL研究

2021-07-31

freve (审核中...)

前往app查看评论内容

#难治性#

Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤

2021-07-29

freve (审核中...)

前往app查看评论内容

#难治性#

Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验

2021-07-29

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet：肾动脉超声消融治疗难治性高血压效果明显（RADIANCE-HTN TRIO研究）

2021-07-27

freve (审核中...)

前往app查看评论内容

#难治性#

EuroIntervention：肾动脉超声消融治疗难治性高血压长期随访结果公布（RADIANCE-HTN SOLO研究）

2021-07-27

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效

2021-07-17

freve (审核中...)

前往app查看评论内容

#难治性#

J Allergy Clin Immunol Pract：利多卡因喷雾剂可有效减少难治性慢性咳嗽患者的咳嗽频率

2021-07-16

freve (审核中...)

前往app查看评论内容

#难治性#

Nat Med：局部输注HER2特异性CAR-T细胞治疗复发性/难治性中枢神经系统肿瘤儿童和年轻患者的临床研究

2021-07-16

freve (审核中...)

前往app查看评论内容

#难治性#

Int J Hematol：罗米布司汀可有效治疗艾曲波帕难治性再生障碍性贫血

2021-07-15

freve (审核中...)

前往app查看评论内容

#难治性#

Molecular Cell:难治性乳腺癌的潜在药物靶点：RNA结合蛋白YTHDF2

2021-07-05

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol: 帕博利珠单抗+GVD（吉西他滨、长春瑞宾和脂质体阿霉素）二线治疗复发或难治性经典霍奇金淋巴瘤的疗效和安全性

2021-06-28

freve (审核中...)

前往app查看评论内容

#难治性#

Eur J Cancer：瑞戈非尼或可成为复发性/难治性实体肿瘤患儿的新选择！

2021-06-26

柳叶一刀 (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解

2021-06-26

freve (审核中...)

前往app查看评论内容

#难治性#

Leukemia：研究支持首次复发后的复发/难治性多发性骨髓瘤患者使用D-RD

2021-06-25

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后

2021-06-18

科室
- - 订阅+
  - 更多科室
工具
服务